Rhelion Life Sciences has reappointed Dr. Robin Carhart-Harris as Scientific Advisor to support its research and development in the legal psychedelic sector, particularly through its subsidiary Filament Health. Dr. Carhart-Harris, a leading expert in neurology and psychiatry, will provide scientific guidance and help expand research collaborations. The company recently acquired Filament Health and its patented psilocybin drug candidate PEX010, which is used in clinical studies worldwide. Rhelion also announced a debt settlement and granted stock options to employees, signaling ongoing growth and development in its psychedelic drug programs.
Rhelion Life Sciences' recent reappointment of Dr. Robin Carhart-Harris as Scientific Advisor is provided here with a snapshot of the health sector on Pluang as of Oct 14, 2026, 19:01 WIB. Among 150 priced US health stocks, 105 advanced while 40 declined. Notable movers include BioNano Genomics Inc (BNGO) at USD 1.39 with 98% sell order activity, AstraZeneca plc (AZN) at USD 158.67 with 58% sell orders, and Novartis AG (NVS) at USD 144.94 with 82% sell orders, reflecting varied investor sentiment and typical hold times ranging from 50 to 127 days.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
